Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VelCD Induction in Untreated Multiple Myeloma
NCT00833560Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2006
- Primary completion
- Jun 2009
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib in multiple myeloma (MM), sponsored by Janssen Pharmaceutical. Started Mar 2006; status: completed.
02
Drugs
bortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00833560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00833560.